Published in Drug Law Weekly, February 8th, 2005
Beckman Coulter intends to use the HMGB1 technology to develop an immunoassay for detection and management of inflammatory diseases. In return, Critical Therapeutics will receive a license fee, as well as the potential for future development milestones and royalties contingent on sales of any diagnostic...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.